Eosinophilic Granulomatosis with Polyangiitis (EGPA)


Sponsor is doing this research to find out if an experimental medication, benralizumab, will work and be safe for the treatment of EGPA. To see if benralizumab has an impact in treating EGPA, this study will compare it with an active comparator, mepolizumab, that has regulatory approval in several markets for use in patients with EGPA.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 80

Inclusion criteria:

You might be eligible to participate in this trial if:

1) you are 18 years of age and older
2) you have EGPA.

Exclusion criteria:

You might not be eligible to participate in this trial if:

1) you do not have EGPA
2) you are pregnant
3) you are under the age of 18.


This study is not currently accepting expressions of interest via the website. Please see contact information below.

Additional information

Contact information

If you would like to learn more about how you can get involved with this trial, please contact our study coordinator, Linda, at 403-220-8680.

Principal investigator:

Brandie Walker

Clinical trial: